Good drug, bad luck: business, regulatory issues can create obstacles for drug development.
Goldman
Bruce
B
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015195:Drug Design; D004341:Drug Evaluation / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000592:standards; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D011355:Prodrugs / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011355:Prodrugs; D019275:Radiopharmaceuticals; C061972:samarium Sm-153 lexidronam; D002955:Leucovorin; D005472:Fluorouracil